Introduction to Acral Melanoma

Acral melanoma, also known as melanoma acrale, is a rare and distinct subtype of melanoma that arises on the hairless skin of the palms, soles, and beneath the nail beds (subungual region). Unlike the more common cutaneous melanomas strongly linked to ultraviolet (UV) radiation exposure, acral melanoma occurs in sun-shielded areas, presenting unique challenges in understanding its etiology and detection. Globally, it accounts for a small percentage of all melanomas—approximately 2-3% in Caucasian populations—but its relative incidence is significantly higher in populations with darker skin phototypes. For instance, in Asian populations, acral melanoma can constitute up to 50% of all melanoma cases, and in Black populations, it is the most prevalent form. In Hong Kong, a 2022 study from the Hong Kong Cancer Registry indicated that acral melanoma represents nearly 40% of melanoma diagnoses, highlighting its disproportionate impact in the region compared to Western countries.

One of the most critical and concerning characteristics of acral melanoma is its tendency to be diagnosed at a later, more advanced stage. Several factors contribute to this delay. Firstly, its location on less visible areas like the soles of the feet or between toes means lesions can go unnoticed for extended periods. Secondly, early signs can be mistaken for benign conditions such as bruises, warts, fungal infections, or non-healing ulcers. A specific clinical variant, melanoma acrale lentigginoso palmo mano, which presents as a slowly enlarging, irregularly pigmented patch on the palm or sole, can be particularly insidious, evolving over years before raising alarm. This diagnostic lag often results in a thicker primary tumor (higher Breslow depth) at the time of discovery, which is a key prognostic factor associated with a higher risk of metastasis and poorer outcomes. Public and even some medical awareness is frequently focused on sun-exposed skin, leaving acral sites under-scrutinized during routine checks.

Risk Factors and Causes

The pathogenesis of acral melanoma remains less clear than that of its sun-related counterparts, making its risk profile distinct and an active area of research.

UV Exposure: Is it a Factor?

Unlike most cutaneous melanomas, direct and cumulative UV radiation is not considered a primary causative factor for acral melanoma. This is evidenced by its occurrence in perpetually covered body parts. However, some researchers hypothesize that systemic effects of UV exposure or indirect mechanisms could play a minor, modulatory role. The prevailing consensus is that other, more dominant factors are at play, shifting the research focus away from sun protection as a primary preventive measure for this specific subtype.

Genetic Predisposition

Genetic alterations are central to the development of acral melanoma. The mutational signature differs markedly from UV-induced melanomas. Common driver mutations include amplifications in the CCND1, CDK4, and KIT genes, as well as structural variations. Mutations in the BRAF gene, common in other melanomas, are relatively rare in acral cases. This distinct genetic landscape has direct implications for targeted therapy options. Furthermore, certain inherited genetic syndromes, such as familial atypical multiple mole melanoma (FAMMM) syndrome, may confer a slightly increased risk for all melanoma types, including acral, though the link is not as strong.

Other Potential Risk Factors

Research is ongoing into other potential contributors. Chronic trauma or pressure to the palms and soles has been proposed as a possible co-factor, though evidence is largely anecdotal. Some studies suggest a link with acral melanoma and certain occupations or activities involving repeated friction. Immunosuppression is a known risk factor for melanoma in general and may apply to acral forms as well. Demographic factors are significant: individuals with darker skin tones have a higher relative risk of developing acral melanoma compared to other subtypes. Age is also a factor, with diagnosis being more common in older adults, though it can occur at any age.

Symptoms and Detection

Vigilance regarding the specific symptoms and locations of acral melanoma is paramount for early detection.

Common Locations (Hands, Feet, Nail Beds)

Acral melanoma most frequently manifests on weight-bearing areas like the soles, especially the heel or forefoot. It is also found on the palms, fingers, toes, and in the nail apparatus (subungual melanoma). Subungual melanoma often presents as a longitudinal brown or black band on the nail (melanonychia) that widens over time, and may be accompanied by nail dystrophy, pigmentation spreading to the surrounding skin (Hutchinson's sign), or a nodule under the nail.

The ABCDEs of Melanoma and Acral Melanoma Variations

The classic ABCDE rule (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolution) is a useful guide but requires adaptation for acral sites. Here, the "C" for color can be particularly telling, showing shades of tan, brown, black, blue, red, or even white. A more specific and critical mnemonic for acral and subungual melanoma is the "ABCDEF" rule:

• Age: Peak incidence in 5th-7th decades, and ethnic groups of color.
• Band: Brown or black band on the nail, breadth >3mm, blurred borders.
• Change: Rapid change in size or growth rate of the band/nail lesion.
• Digit: Thumb, great toe, and index finger are most commonly involved.
• Extension of pigment to the nail fold (Hutchinson's sign).
• Family or personal history of melanoma or dysplastic nevus.

Importance of Regular Self-Exams and Professional Skin Checks

Given its hidden location, proactive examination is crucial. Individuals should perform monthly self-exams in good light, using a mirror or asking for assistance to inspect the entire surface of soles, between toes, palms, and fingernails/toenails. Any new, changing, or unusual lesion should prompt a visit to a dermatologist. Healthcare professionals must include acral sites in full-body skin examinations, especially for high-risk individuals. Dermoscopy, a non-invasive imaging technique, is invaluable for evaluating pigmented lesions on acral skin, revealing specific patterns like the parallel ridge pattern, which is highly suggestive of early acral melanoma.

Diagnosis and Staging

Once a suspicious lesion is identified, a definitive diagnosis and accurate staging guide all subsequent management.

Biopsy Procedures

A biopsy is mandatory. For small lesions, an excisional biopsy (removing the entire lesion with a narrow margin) is preferred to allow for accurate measurement of tumor thickness (Breslow depth). For larger lesions on functionally sensitive areas, an incisional or punch biopsy of the most clinically suspicious area may be performed. The biopsy sample is sent for histopathological examination, where a pathologist will assess critical features like Breslow depth, ulceration, mitotic rate, and the presence of regression. Immunohistochemical stains (e.g., HMB-45, Melan-A, SOX10) are used to confirm the melanocytic origin of the cells. It is during this detailed analysis that a pathologist must carefully differentiate acral melanoma from other benign or malignant mimics, such as a melanoma di spitz (Spitz nevus), which is typically a benign melanocytic lesion more common in children and young adults but can sometimes have concerning histological features requiring expert interpretation.

Staging System for Acral Melanoma

Acral melanoma is staged using the same American Joint Committee on Cancer (AJCC) TNM system (8th Edition) as other cutaneous melanomas. This system evaluates:

The Impact of Staging on Treatment Options

Staging directly dictates the treatment pathway. Early-stage (Stage 0-II) disease is primarily managed with surgery, with the extent of resection and the need for SLNB determined by the T category. Stage III disease (regional lymph node involvement) requires more extensive lymph node surgery and often adjuvant systemic therapy. Stage IV disease (metastatic) is primarily treated with systemic therapies, with surgery potentially used for symptom control. Accurate staging is therefore the cornerstone of personalized treatment planning.

Treatment Options

The management of acral melanoma is multidisciplinary, involving dermatologists, surgical oncologists, medical oncologists, and pathologists. Treatment strategies have evolved significantly with the advent of novel therapies.

Surgical Excision

Surgery is the mainstay of treatment for localized acral melanoma. The goal is complete removal with clear histological margins. The recommended margin width depends on the Breslow thickness, ranging from 0.5-1 cm for in situ lesions to 2 cm for thicker tumors. For subungual melanoma, this often requires amputation of the digit at the appropriate joint to achieve adequate margins. In some select, very early cases, functional-sparing surgeries (e.g., wide excision with skin grafting) may be considered. SLNB is typically performed concurrently with wide excision for tumors with a thickness >0.8 mm.

Targeted Therapy

For metastatic or unresectable acral melanoma with specific genetic alterations, targeted drugs can be highly effective. While BRAF/MEK inhibitors (e.g., dabrafenib/trametinib) are used less frequently due to lower mutation rates, agents targeting KIT mutations (e.g., imatinib) or NRAS mutations are options for the subset of patients whose tumors harbor these alterations. Tumor genetic profiling (next-generation sequencing) is essential to identify actionable targets.

Immunotherapy

Immunotherapy has revolutionized the treatment of advanced melanoma, including acral subtypes. Checkpoint inhibitors such as anti-PD-1 antibodies (pembrolizumab, nivolumab) and anti-CTLA-4 antibody (ipilimumab) work by releasing the brakes on the patient's own immune system to attack cancer cells. These agents are now standard first-line treatments for Stage III (adjuvant) and Stage IV disease. Response rates in acral melanoma can be slightly lower than in other subtypes, but durable responses are still achieved in a significant proportion of patients.

Chemotherapy (When Applicable)

Traditional chemotherapeutic agents like dacarbazine or temozolomide have limited efficacy and are now rarely used as first-line treatments due to the superior outcomes with immunotherapy and targeted therapy. They may be considered in specific circumstances where other options are exhausted or contraindicated.

Clinical Trials

Participation in clinical trials is a critical avenue for accessing cutting-edge therapies. Given the rarity and distinct biology of acral melanoma, dedicated trials are essential. Current research explores novel immunotherapy combinations, adoptive cell therapies (like TIL therapy), and new targeted agents. Patients are encouraged to discuss trial eligibility with their oncologists.

Prognosis and Survival Rates

The prognosis of acral melanoma is historically perceived as poorer than other subtypes, largely due to later-stage diagnosis. However, outcomes are heavily influenced by stage at diagnosis and have improved with modern therapies.

Factors Affecting Prognosis

The single most important prognostic factor is the Breslow thickness of the primary tumor. Ulceration is another powerful negative predictor. Lymph node involvement (Stage III) significantly worsens prognosis compared to localized disease (Stage I/II). The presence and site of distant metastases (Stage IV) carry the poorest outlook, though survival has improved. Other factors include mitotic rate, patient age, and overall health. The distinct genetic profile of melanoma acrale may also influence biological aggressiveness and response to treatment.

Recent Advances Improving Survival

The introduction of effective systemic therapies has markedly changed the survival landscape for advanced acral melanoma. Data from Hong Kong and global studies show that the 5-year survival rates for Stage IV disease, while still lower than for earlier stages, have increased in the era of immunotherapy and targeted therapy compared to the chemotherapy era. Early detection remains the most powerful tool for improving prognosis, emphasizing the need for continued public and professional education about this rare cancer.

Prevention and Early Detection Strategies

While primary prevention is challenging due to the unclear etiology, secondary prevention through early detection is the most actionable strategy.

Protecting Hands and Feet from Sun Exposure (Though UV Link Unclear)

Although the direct causal link is weak, practicing general sun safety is still recommended for overall skin health. This can include applying broad-spectrum sunscreen to the tops of hands and feet when they are exposed. More importantly, the focus should be on injury prevention and being mindful of any non-healing wounds or persistent lesions on acral sites.

Regular Skin Exams and Professional Screening

Establishing a routine of monthly self-skin examinations that explicitly include the palms, soles, and nails is the cornerstone of early detection. Individuals with a personal or family history of melanoma, those with many moles, or people with darker skin types should be particularly vigilant. Annual professional skin exams by a dermatologist are recommended for high-risk individuals, and these exams must always be comprehensive, including acral surfaces. Raising awareness among primary care physicians and podiatrists to recognize potential signs is also crucial.

Support Resources for Patients and Families

A diagnosis of a rare cancer like acral melanoma can be isolating. Access to reliable information and support networks is vital.

Organizations Offering Support and Information

International organizations such as the Melanoma Research Alliance (MRA), the Skin Cancer Foundation, and the American Cancer Society provide extensive educational materials on all melanoma types. For region-specific support in Hong Kong, the Hong Kong Cancer Fund and the Melanoma & Skin Cancer Support Group under the Hong Kong Anti-Cancer Society offer counseling, patient support groups, and practical assistance. These resources help patients navigate treatment decisions, understand their diagnosis, and connect with others on a similar journey.

Coping with a Diagnosis

Coping involves addressing both the physical and emotional challenges. Building a trusted relationship with the medical team, seeking second opinions if desired, and asking detailed questions about treatment plans are empowering steps. Managing treatment side effects, maintaining nutrition, and engaging in gentle physical activity as tolerated can improve quality of life. Psychological support from counselors, therapists, or support groups can help manage anxiety, depression, and the stress of a cancer diagnosis. It's also important for caregivers and family members to seek support for themselves.

Hope and Progress in Acral Melanoma Research

The landscape of acral melanoma management is one of rapidly evolving hope. Once considered a neglected area with limited treatment options, it is now at the forefront of precision oncology. The distinct genetic characterization of tumors like melanoma acrale lentigginoso palmo mano is driving the development of more tailored therapies. International research collaborations are focusing on understanding the unique biology and immune microenvironment of acral melanoma to improve immunotherapy efficacy. Advances in liquid biopsies for monitoring disease and detecting recurrence earlier are on the horizon. While challenges remain, particularly in promoting global awareness for earlier diagnosis, the progress in therapeutic options has provided tangible hope for improved survival and quality of life for patients. Continued investment in research, coupled with persistent education to ensure no spot is overlooked—whether a changing mole on the back or a new line on a nail—holds the promise of turning the tide against this rare but serious form of skin cancer.